drugset / Trial / NCT07070466

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

NCT07070466

NaSingle-groupOpen-labelTreatment

Summary

This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.

Timeline

Start
2025-10-10
Primary completion
2026-12-01
Completion
2028-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivonescimab Monoclonal antibody Intravenous
Background Leucovorin Small molecule Intravenous
Background Oxaliplatin Small molecule Intravenous
Background fluorouracil Small molecule Intravenous